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Accepted 6 August 2015Acute myeloid leukemia (AML) and myelodysplastic
syndromes (MDS) represent the most frequent indications
for allogeneic blood stem cell transplantation (allo-SCT) in
Europe and the United States [1]. Advances in donor selec-
tion, immunosuppression, and supportive care, as well as
the introduction of reduced-toxicity conditioning, have
improved outcomes and also broadened the access for more,
in particular older, patients to this potentially curative
treatment option [2]. Furthermore, through the use of
alternative donor sources, such as haploidentical family
members, the frequency of allo-SCTs, not only for myeloid
disorders, will probably continue to grow [1].
Despite these developments in patient as well as in donor
selection, and the advances concerning the direct trans-
plantation phase, relapse still represents the main cause of
treatment failure and the most challenging therapeutic
hurdle in the post-transplantation period. Treatment options
in this situation consist of palliative care, low-dose or
intensive chemotherapy, as well as cellular therapies, such as
donor lymphocyte infusions (DLI), and second trans-
plantation in selected cases. However, many patients can
either not tolerate intensive therapies or are refractory to
those interventions [3]. Recently, based on its efﬁcacy,
manageable toxicities, and low graft-versus-host disease
(GVHD) rate, the combination of the hypomethylating agent
azacitidine (Aza) and DLI has proven to be a valuable alter-
native, either when given preemptively or as salvage therapy
for overt hematologic relapse [4]. Nevertheless, 2-year sur-
vival rates after any intervention for relapse after allo-SCT
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for improvement [3,4].
One potential approach to reduce the risk of AML or MDS
relapse after allo-SCT could be maintenance ordeven
betterdconsolidation therapy. By a direct antileukemic
effect, such post-transplantation treatment may be either
able to directly eliminate minimal residual disease or to
control disease activity until the donor immune system is
sufﬁciently reconstituted tomediate a graft-versus-leukemia
(GVL) effect. Ideally, a suitable maintenance treatment would
even promote GVL reactions without increasing the risk for
GVHD.
With the goal of introducing a drug carrying these
properties, Pusic et al. here present the results of a pro-
spective, dose-ﬁnding study of decitabine (DAC) after
allo-SCT [5]. This DNA methyltransferase inhibitor was
administered to 24 patients with high-risk AML or MDS in
remission starting a median of 95 days (range, 62 to 115)
after allo-SCT. According to the study design, no formal
maximum-tolerated dose was reached and the major
conclusion by the authors from this study is that DAC can
be given safely in an outpatient setting. Still, only 9 of 22
evaluable patients were able to complete all 8 envisaged
cycles, whereas 13 patients prematurely discontinued the
study, including 5 because of toxicity. As a consequence,
authors concluded that 10 mg/m2, rather than the highest
dose level of 15 mg/m2 per day, for 5 days every 6 weeks
may be a better tolerated dose for subsequent studies.
Two-year overall survival, disease-free survival, and cu-
mulative incidence of relapse in this study were 56%, 48%,
and 28%, respectively. As this is a small, early phase, non-
randomized trial, a deﬁnitive ranking of outcome results is
impossible, but this interesting study of Pusic et al.
addresses some important issues in the context of relapse
prevention after allo-SCT.
First, so far no post-transplantation therapy for myeloid
diseases has been approved because of lack of results from
well-designed, prospective, placebo-controlled random-
ized trials. Indeed, early-phase studies as that presented
here and a number of currently ongoing trials investigating
post-transplantation therapy in patients with AML or MDS
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“allogeneic” and “maintenance”), represent an essential
ﬁrst step to establishing innovative post-transplantation
strategies to reduce the incidence of relapse after allo-
SCT for patients with high-risk myeloid malignancies.
Next, a better understanding of relapse biology and how
drugs such as Aza or DAC mediate their action in the post-
transplantation period is deﬁnitively needed. For example,
it has been shown previously that Aza can induce expansion
of regulatory T cells in humans after allo-SCT, which may be
the reason for a relatively low incidence of GVHD, even after
DLI [6]. For DAC, similar ﬁndings have been shown inmice by
the same group reporting here on the clinical trial [7]. In
contrast to the results in mice and also in contrast to Aza, no
effect of DAC on Tregs was found in the current study.
Furthermore, although acute GVHDwas mild, DAC treatment
did not inﬂuence chronic GVHD [5]. This discrepancy may be
related to the fact that regulatory T cells were only investi-
gated in peripheral blood, to pharmacodynamic differences
between DAC and Aza, as well as to the relatively long in-
terval between transplantation and beginning of DAC
therapy.
Finally, 11 patients developed grade III or IV neutropenia,
33% developed grade III or IV infections, and 3 patients died
because of infections, highlighting the risks of post-
transplantation cytotoxic treatment.
Allo-SCT is a curative therapy and many patients with
high-risk myeloid malignancies have a chance to achieve
long-term cure without post-transplantation therapy. It is
obvious that, for some patients, DAC given after trans-
plantation is overtreatment with potentially detrimental
side effects. Thus, in the future, special attention must be
paid to patient selection in terms of relapse risk.
One approach for better risk stratiﬁcation could be the
knowledge of the adverse prognosis of karyotype alterations,
gene mutations, and their combination. For example, some
studies have shown that TP53 mutations indicate a dismal
prognosis for MDS patients after allo-SCT and may be able to
subdivide patients with complex karyotypes with regard to
their prognosis [8]. The goal is to identify a patient popula-
tion with an extraordinary high relapse risk for further
studies of innovative post-transplantation strategies applied
in remission. In patients with an intermediate risk for relapse
after allo-SCT, overtreatment should be avoided. Therefore,
minimal residual diseaseetriggered preemptive therapy,including DLI instead of treatment in remission, may be a
better strategy, as recent studies have shown that this
strategy can achieve excellent outcomes.
In summary, studies such as the one of Pusic et al.
represent important ﬁrst steps towards successful post-
transplantation therapies for patients with AML or MDS.
Better understanding of disease biology, and thereby patient
selection, as well as a growing number of antileukemic and
immunomodulating drugs, will hopefully help to close the
gap between conditioning regimen and long-term disease
control by the GVL effect.
ACKNOWLEDGMENT
Financial disclosure: T.S. had a consulting role for Celgene
Corporation, Germany and received ﬁnancial travel support
and lecture fees from Celgene Corporation, Germany. G.K.
received ﬁnancial travel support, research funding and lec-
ture fees from Celgene Corporation, Germany.
REFERENCES
1. Sureda A, Bader P, Cesaro S, et al. Indications for allo- and auto-SCT for
haematological diseases, solid tumours and immune disorders: current
practice in Europe, 2015. Bone Marrow Transplant. 2015;50:1037-1056.
2. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after alloge-
neic hematopoietic-cell transplantation. N Engl J Med. 2010;363:
2091-2101.
3. de Lima M, Porter DL, Battiwalla M, et al. Proceedings from the National
Cancer Institute’s Second International Workshop on the Biology, Pre-
vention, and Treatment of Relapse After Hematopoietic Stem Cell
Transplantation: part III. prevention and treatment of relapse after
allogeneic transplantation. Biol Blood Marrow Transplant. 2014;20:4-13.
4. Schroeder T, Rachlis E, Bug G, et al. Treatment of acute myeloid leukemia
or myelodysplastic syndrome relapse after allogeneic stem cell trans-
plantation with azacitidine and donor lymphocyte infusionsea retro-
spective multicenter analysis from the German Cooperative Transplant
Study Group. Biol Blood Marrow Transplant. 2015;21:653-660.
5. Pusic I, Choi J, Fiala MA, et al. Maintenance therapy with decitabine after
allogeneic stem cell transplantation for acute myelogenous leukemia
and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2015;21:
1761-1769.
6. Schroeder T, Frobel J, Cadeddu RP, et al. Salvage therapy with azacitidine
increases regulatory T cells in peripheral blood of patients with AML or
MDS and early relapse after allogeneic blood stem cell transplantation.
Leukemia. 2013;27:1910-1913.
7. Choi J, Ritchey J, Prior JL, et al. In vivo administration of hypomethylating
agents mitigate graft-versus-host disease without sacriﬁcing graft-
versus-leukemia. Blood. 2010;116:129-139.
8. Bejar R, Stevenson KE, Caughey B, et al. Somatic mutations predict poor
outcome in patients with myelodysplastic syndrome after hematopoietic
stem-cell transplantation. J Clin Oncol. 2014;32:2691-2698.
